World Health Organization and Beyond: New Aspects in the Pathology of an Old Disease

Hematology/Oncology Clinics of North America

Volumn 21, Issue 5, 2007, Pages 769-786

  Hummel, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CASPASE 3; CD30 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; RITUXIMAB; TRANSCRIPTION FACTOR PAX5;

B LYMPHOCYTE; CANCER RADIOTHERAPY; CLASSICAL HODGKIN LYMPHOMA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; NONHODGKIN LYMPHOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REED STERNBERG CELL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPH NODES; REED-STERNBERG CELLS; WORLD HEALTH ORGANIZATION;

EID: 34748866633     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.015     Document Type: Review

References (100)

1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Medical Chirurgical Transaction 17 (1832) 68-114
2. Wilks S. Cases of lardaceous disease and some allied affections, with remark. Guys Hosp Rep 17 (1856) 103-132
3. Wilks S. Cases with enlargement of the lymphatic glands and spleen (or Hodgkin's disease), with remarks. Guys Hospital Reports 11 (1865) 57
4. Wunderlich C.A. Zwei Fälle von progressiven multiplen Lymphdrüsenhypertrophien. Archiv für physiologische Heilkunde 12 (1858) 122-131
5. Trousseau A. De l'adénie. Clin méd l'Hotel-Dieu Paris 3 (1865) 874-875
6. Langhans T. Das maligne lymphosarkom (pseudoleukämie). Virchow's Archiv f path Anatomie 54 (1872) 509-537
7. Greenfield W.S. Specimens illustrative of the pathology of lymphadenoma and leucocythemia. Trans Path Soc London 29 (1878) 272-304
8. Sternberg C. Über eine eigenartige unter dem Bilde der Pseudoleukämie verlaufende Tuberculose des lymphatischen Apparates. Ztschr Heilk 19 (1898) 21-90
9. Reed D.M. On the pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. John Hopkins Hosp Rep 10 (1902) 133-196
10. Fox H. Remarks on the microscopical preparations made from some of the original tissue described by Thomas Hodgkin 1832. Ann Med Hist 8 (1926) 370-374
11. Jackson H.L., Parker F., et al. Hodgkin's disease and allied disorders (1947), Oxford University Press, New York
12. Lukes R.J., and Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 26 (1966) 1063-1083
13. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
14. Jaffe E.S., Harris N.L., Stein H., et al. Tumours of haematopoietic and lymphoid tissues (2001), IARCPress, Lyon (France)
15. Anagnostou D., Parker J.W., Taylor C.R., et al. Lacunar cells of nodular sclerosing Hodgkin's disease: an ultrastructural and immunohistologic study. Cancer 39 (1977) 1032-1043
16. Lorenzen J., Thiele J., and Fischer R. The mummified Hodgkin cell: cell death in Hodgkin's disease. J Pathol 182 (1997) 288-298
17. Hess J.L., Bodis S., Pinkus G., et al. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 74 (1994) 708-714
18. van Spronsen D.J., Vrints L.W., Hofstra G., et al. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92. Br J Haematol 96 (1997) 322-327
19. Diehl V., Sextro M., Franklin J., et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17 (1999) 776-783
20. Neiman R.S., Rosen P.J., and Lukes R.J. Lymphocyte-depletion Hodgkin's disease. A clinicopathological entity. N Engl J Med 288 (1973) 751-755
21. Anagnostopoulos I., Hansmann M.L., Franssila K., et al. European Task Force on lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96 (2000) 1889-1899
22. Stein H., Marafioti T., Foss H.D., et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97 (2001) 496-501
23. Marafioti T., Hummel M., Anagnostopoulos I., et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337 (1997) 453-458
24. Braeuninger A., Kuppers R., Strickler J.G., et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 94 (1997) 9337-9342
25. Ohno T., Stribley J.A., Wu G., et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 337 (1997) 459-465
26. Schwab U., Stein H., Gerdes J., et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299 (1982) 65-67
27. Pinkus G.S., Thomas P., and Said J.W. Leu-M1-a marker for Reed-Sternberg cells in Hodgkin's disease. An immunoperoxidase study of paraffin-embedded tissues. Am J Pathol 119 (1985) 244-252
28. Olsson L. On the natural biology of the malignant cells in Hodgkin's disease. Int J Radiat Oncol Biol Phys 11 (1985) 37-48
29. Bargou R.C., Mapara M.Y., Zugck C., et al. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. J Exp Med 177 (1993) 1257-1268
30. Ree H.J., Khan A.A., Qureshi M.N., et al. Expression of cell adhesion molecules associated with germinal center in Hodgkin's disease: an immunohistochemical study. The germinal center related complex and histologic subtypes. Cancer 73 (1994) 1257-1263
31. Strauchen J.A., and mitriu-Bona A. Immunopathology of Hodgkin's disease. Characterization of Reed-Sternberg cells with monoclonal antibodies. Am J Pathol 123 (1986) 293-300
32. Stein H., Mason D.Y., Gerdes J., et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66 (1985) 848-858
33. Durkop H., Latza U., Hummel M., et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68 (1992) 421-427
34. Gerdes J., Schwarting R., and Stein H. High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. J Clin Pathol 39 (1986) 993-997
35. Tamaru J., Hummel M., Zemlin M., et al. Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 84 (1994) 708-715
36. Kuppers R., Rajewsky K., Zhao M., et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 91 (1994) 10962-10966
37. Hummel M., Marafioti T., Ziemann K., et al. Ig rearrangements in isolated Reed-Sternberg cells: conclusions from four different studies. Ann Oncol 7 Suppl 4 (1996) 31-33
38. Hummel M., Ziemann K., Lammert H., et al. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N Engl J Med 333 (1995) 901-906
39. Marafioti T., Hummel M., Foss H.D., et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95 (2000) 1443-1450
40. Seitz V., Hummel M., Marafioti T., et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95 (2000) 3020-3024
41. Muschen M., Rajewsky K., Brauninger A., et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 191 (2000) 387-394
42. Kanzler H., Kuppers R., Hansmann M.L., et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184 (1996) 1495-1505
43. Ushmorov A., Ritz O., Hummel M., et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 104 (2004) 3326-3334
44. Ushmorov A., Leithauser F., Sakk O., et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 107 (2006) 2493-2500
45. Marafioti T., Hummel M., Anagnostopoulos I., et al. Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol 17 (1999) 3804-3809
46. Mathas S., Janz M., Hummel F., et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 7 (2006) 207-215
47. Stein H., Hummel M., Durkop H., et al. Biology of Hodgkin's disease. In: Canellos G.P., Lister T.A., and Sklar J.L. (Eds). The lymphomas (2007), W.B. Saunders, Philadelphia 287-304
48. Foss H.D., Reusch R., Demel G., et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 94 (1999) 3108-3113
49. Hertel C.B., Zhou X.G., Hamilton-Dutoit S.J., et al. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 21 (2002) 4908-4920
50. Dallenbach F.E., and Stein H. Expression of T-cell-receptor beta chain in Reed-Sternberg cells. Lancet 2 (1989) 828-830
51. Kadin M.E., Muramoto L., and Said J. Expression of T-cell antigens on Reed-Sternberg cells in a subset of patients with nodular sclerosing and mixed cellularity Hodgkin's disease. Am J Pathol 130 (1988) 345-353
52. Krenacs L., Wellmann A., Sorbara L., et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood 89 (1997) 980-989
53. Oudejans J.J., Kummer J.A., Jiwa M., et al. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 148 (1996) 233-240
54. Drexler H.G. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk Lymphoma 8 (1992) 283-313
55. Pinkus G.S., Pinkus J.L., Langhoff E., et al. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease. Evidence for a dendritic or B cell derivation?. Am J Pathol 150 (1997) 543-562
56. Carbone A., Gloghini A., Volpe R., et al. Anti-vimentin antibody reactivity with Reed-Sternberg cells of Hodgkin's disease. Virchows Arch A Pathol Anat Histopathol 417 (1990) 43-48
57. Carbone A., Gloghini A., Aldinucci D., et al. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 117 (2002) 366-372
58. Falini B., Fizzotti M., Pucciarini A., et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95 (2000) 2084-2092
59. Bargou R.C., Leng C., Krappmann D., et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87 (1996) 4340-4347
60. Hatada E.N., Krappmann D., and Scheidereit C. NF-kappaB and the innate immune response. Curr Opin Immunol 12 (2000) 52-58
61. Krappmann D., and Scheidereit C. Regulation of NF-kappa B activity by I kappa B alpha and I kappa B beta stability. Immunobiology 198 (1997) 3-13
62. Wood K.M., Roff M., and Hay R.T. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene 16 (1998) 2131-2139
63. Emmerich F., Meiser M., Hummel M., et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94 (1999) 3129-3134
64. Cabannes E., Khan G., Aillet F., et al. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18 (1999) 3063-3070
65. Emmerich F., Theurich S., Hummel M., et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 201 (2003) 413-420
66. Horie R., Watanabe T., Morishita Y., et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21 (2002) 2493-2503
67. Annunziata C.M., Safiran Y.J., Irving S.G., et al. Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. Blood 96 (2000) 2841-2848
68. Hinz M., Lemke P., Anagnostopoulos I., et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196 (2002) 605-617
69. Rodig S.J., Savage K.J., Nguyen V., et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol 29 (2005) 196-203
70. Dukers D.F., Meijer C.J., ten Berge R.L., et al. High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. Blood 100 (2002) 36-42
71. Tzankov A., Zimpfer A., Went P., et al. Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. Mod Pathol 18 (2005) 90-96
72. Tzankov A., Zimpfer A., Lugli A., et al. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol 199 (2003) 201-207
73. Berglund M., Flordal E., Gullander J., et al. Molecular cytogenetic characterization of four commonly used cell lines derived from Hodgkin lymphoma. Cancer Genet Cytogenet 141 (2003) 43-48
74. Joos S., Kupper M., Ohl S., et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60 (2000) 549-552
75. Martin-Subero J.I., Klapper W., Sotnikova A., et al. Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res 66 (2006) 10332-10338
76. Weiss L.M., Strickler J.G., Warnke R.A., et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 129 (1987) 86-91
77. Herbst H., Niedobitek G., Kneba M., et al. High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol 137 (1990) 13-18
78. Knecht H., Odermatt B.F., Bachmann E., et al. Frequent detection of Epstein-Barr virus DNA by the polymerase chain reaction in lymph node biopsies from patients with Hodgkin's disease without genomic evidence of B- or T-cell clonality. Blood 78 (1991) 760-767
79. Hummel M., Anagnostopoulos I., Dallenbach F., et al. EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products. Br J Haematol 82 (1992) 689-694
80. Wu T.C., Mann R.B., Charache P., et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 46 (1990) 801-804
81. Herbst H. Epstein-Barr virus in Hodgkin's disease. Semin Cancer Biol 7 (1996) 183-189
82. Hummel M., Anagnostopoulos I., Korbjuhn P., et al. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J Pathol 175 (1995) 263-271
83. Herbst H., Dallenbach F., Hummel M., et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A 88 (1991) 4766-4770
84. Bechtel D., Kurth J., Unkel C., et al. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 106 (2005) 4345-4350
85. Renne C., Willenbrock K., Kuppers R., et al. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 105 (2005) 4051-4059
86. Renne C., Hinsch N., Willenbrock K., et al. The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma. Int J Cancer 120 (2007) 2504-2509
87. Abbondanzo S.L., Sato N., Straus S.E., et al. Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol 93 (1990) 698-702
88. Stein H., Johrens K., and Anagnostopoulos I. Non-mediastinal grey zone lymphomas and report from the workshop. Eur J Haematol Suppl 66 (2005) 42-44
89. Banks P.M. The distinction of Hodgkin's disease from T cell lymphoma. Semin Diagn Pathol 9 (1992) 279-283
90. Poppema S., Kluiver J.L., Atayar C., et al. Report: workshop on mediastinal grey zone lymphoma. Eur J Haematol Suppl 66 (2005) 45-52
91. Ohno T., Smir B.N., Weisenburger D.D., et al. Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with "Hodgkin's transformation". Blood 91 (1998) 1757-1761
92. Brauninger A., Hansmann M.L., Strickler J.G., et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 340 (1999) 1239-1247
93. Sanchez-Aguilera A., Montalban C., de la C.P., et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108 (2006) 662-668
94. Sup S.J., Alemany C.A., Pohlman B., et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 23 (2005) 3773-3779
95. Natkunam Y., Hsi E.D., Aoun P., et al. Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. Blood 109 (2007) 298-305
96. Alvaro T., Lejeune M., Salvado M.T., et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11 (2005) 1467-1473
97. Asano N., Oshiro A., Matsuo K., et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study. J Clin Oncol 24 (2006) 4626-4633
98. Wahl A.F., Klussman K., Thompson J.D., et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 62 (2002) 3736-3742
99. Visco C., Nadali G., Vassilakopoulos T.P., et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 77 (2006) 387-394
100. Younes A., Romaguera J., Hagemeister F., et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98 (2003) 310-314